Sotera Health

SHC · NASDAQ

$17.93+$0.29 (+1.64%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $17.64

SHC analyst rating

BuyConsensus of 8 analysts over the last 12 months. 88% rate it a buy.

Strong buy0
Buy7
Hold0
Underperform1
Sell0

12-month price target · 11 analysts

Average $23.95 (+33.6% upside)

Low: $22.22
Now: $17.93
High: $26.25

Upgrades and downgrades

The latest rating actions, newest first

SHC analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
JP Morgan	Oct 14, 2026	Downgrade	Neutral → Underweight	$17.00	71%
Citigroup	Aug 7, 2026	Maintains	Buy	$23.00 → $25.00	75%
Barclays	Aug 7, 2026	Maintains	Overweight	$19.00 → $22.00	54%
Piper Sandler	Aug 7, 2026	Maintains	Overweight	$22.00 → $25.00	43%
JP Morgan	Aug 7, 2026	Maintains	Neutral	$16.00 → $18.00	71%
Barclays	Jun 24, 2026	Maintains	Overweight	$18.00 → $19.00	54%
Goldman Sachs	Jun 5, 2026	Initiates	Buy	$20.00	73%
Piper Sandler	May 6, 2026	Maintains	Overweight	$24.00 → $22.00	43%
Barclays	Apr 14, 2026	Maintains	Overweight	$20.00 → $18.00	54%
Citigroup	Feb 24, 2026	Maintains	Buy	$21.00 → $23.00	55%

The case for and against

Updated Oct 18, 2026

Bull case

Sotera Health is positioned favorably because it is delivering consistent top-line beats across all three segments, with 2Q revenue of $321.4M, +8.0% cc, and 1Q revenue of $280.0M, +6.5% cc, while Sterigenics—the largest revenue driver—showed accelerating growth from pricing and volume/mix. Margin performance is also supporting the bullish view, as 2Q adjusted EBITDA margin reached 51.6% and adjusted EPS of $0.26 exceeded expectations, reinforcing management’s ability to convert demand strength into earnings growth. The outlook is further strengthened by higher 2026 guidance, led by revenue of +5.25-6.75% cc and adjusted EBITDA of +5.75-7.25% cc, plus continued litigation de-risking after the New Mexico case settlement and improving visibility in the remaining cases.

Bear case

Sotera Health is facing a less favorable valuation backdrop as peer group multiple compression in recent months has pushed the applied EV/EBITDA multiple down to 12x from 12.5x. The outlook also reflects a one-quarter roll-forward in the valuation framework against an NTM+1 EBITDA projection of $690M, implying limited upside from fundamentals alone. Despite its leading Sterigenics franchise and broad exposure to U.S. healthcare, pharmaceutical, and food safety demand, the company’s earnings multiple appears vulnerable to market de-rating.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.